You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨藥明生物(2269.HK)漲6.65% 今日放榜 預計多賺1.35倍以上
格隆匯 08-23 11:26
格隆匯8月23日丨藥明生物(2269.HK)今日公佈中期業績,上個交易日低見99.2港元創近三個半月新低,今早反彈,現漲6.65%,報112.3港元,最新總市值4761億港元。

公司此前預計上半年淨利潤同比增長135%以上。

近日,國家藥監局官網顯示譽衡生物、藥明生物研發的抗PD-1全人創新抗體藥賽帕利單抗(GLS-010)已進入“在審批”,將於近期獲得NMPA批准上市,用於治療二線以上覆發或難治性經典型霍奇金淋巴瘤(r/r cHL)患者。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account